Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 47
Filter
1.
Parasitol Int ; 85: 102422, 2021 Dec.
Article in English | MEDLINE | ID: mdl-34280531

ABSTRACT

Leishmaniasis is a worldwide problem and has been neglected in a wide range of fields, from diagnosis to treatment. This report describes a case of mucosal leishmaniasis, which may developped after seven decades of an inadequately treated cutaneous lesion. A female patient, 79 years old, from the non-endemic area for leishmaniasis in northern Paraná, presenting mucosal lesion in the nose and throat, reported an "angry ulcer" treated inappropriately as a child when she lived in an endemic region of the state of São Paulo. Indirect immunofluorescence and direct parasite screening were positive. Polymerase chain reaction detected a parasite belonging to the subgenus Leishmania (Viannia) sp. Due to patients limitations, such as low weight and advanced age, the therapeutic model adopted was the combined small doses of Glucantime™ to pentoxifylline, which ensured treatment success.


Subject(s)
Leishmaniasis, Mucocutaneous/prevention & control , Meglumine Antimoniate/therapeutic use , Pentoxifylline/therapeutic use , Trypanocidal Agents/therapeutic use , Aged , Brazil , Drug Therapy, Combination , Female , Humans , Leishmania/drug effects
2.
Emerg Infect Dis ; 25(4): 642-648, 2019 04.
Article in English | MEDLINE | ID: mdl-30882319

ABSTRACT

Mucosal leishmaniasis (ML) is a complication of New World cutaneous leishmaniasis (CL) caused mainly by Leishmania (Viannia) braziliensis. This retrospective study investigated all cases of ML caused by L. (V.) braziliensis in a tertiary medical center in Israel, evaluating the risk factors, clinical presentations, diagnosis, treatment, and outcome of mucosal involvement in ML caused by L. (V.) braziliensis in travelers returning to Israel. During 1993-2015, a total of 145 New World CL cases were seen in travelers returning from Bolivia; among them, 17 (11.7%) developed ML. Nasopharyngeal symptoms developed 0-3 years (median 8 months) after exposure. The only significant risk factor for developing ML was the absence of previous systemic treatment. Among untreated patients, 41% developed ML, compared with only 3% of treated patients (p = 0.005). Systemic treatment for CL seems to be a protective factor against developing ML.


Subject(s)
Communicable Diseases, Imported , Leishmania braziliensis , Leishmaniasis, Mucocutaneous/transmission , Adult , Bolivia , Communicable Diseases, Imported/prevention & control , Communicable Diseases, Imported/transmission , Diagnosis, Differential , Female , Humans , Israel , Leishmania braziliensis/isolation & purification , Leishmaniasis, Mucocutaneous/diagnosis , Leishmaniasis, Mucocutaneous/prevention & control , Leishmaniasis, Mucocutaneous/therapy , Male , Pathology, Molecular , Retrospective Studies , Risk Factors , Skin Diseases, Parasitic , Travel-Related Illness
3.
Guatemala; MSPAS, Departamento de Epidemiología; oct. 2018. 75 p.
Monography in Spanish | LILACS | ID: biblio-1025225

ABSTRACT

Estos protocolos están dirigido a personal médico, paramédico y otros profesionales que realizan acciones gerenciales y operativas de vigilancia epidemiológica en los servicios de salud del país, y están divididos en varios tomos para dar a conocer y actualizar la identificación y medidas de control para diversos padecimientos a fin de continuar con el mejoramiento de las capacidades técnicas de los trabajadores de salud, que permita planificar la prestación de servicios con decisiones partiendo de un enfoque epidemiológico comprobado, para responder a los cambios de tendencias epidemiológicas y con ello contribuir al fortalecimiento de prácticas asertivas de la salud pública de nuestro país.


Subject(s)
Humans , Onchocerciasis/prevention & control , Leishmaniasis/prevention & control , Chagas Disease/prevention & control , Epidemiological Monitoring , Health Surveillance , Leishmaniasis, Mucocutaneous/prevention & control , Leishmaniasis, Cutaneous/prevention & control , Health Surveillance System , Guatemala , Leishmaniasis, Visceral/prevention & control
5.
Vaccine ; 28(46): 7427-35, 2010 Oct 28.
Article in English | MEDLINE | ID: mdl-20851080

ABSTRACT

Adult patients with mucosal leishmaniasis (ML) were enrolled in a randomized, double-blind, placebo-controlled, dose-escalating clinical trial and were randomly assigned to receive three injections of either the LEISH-F1+MPL-SE vaccine (consisting of 5, 10, or 20 µg recombinant Leishmania polyprotein LEISH-F1 antigen+25 µg MPL(®)-SE adjuvant) (n=36) or saline placebo (n=12). The study injections were given subcutaneously on Days 0, 28, and 56, and the patients were followed through Day 336 for safety, immunological, and clinical evolution endpoints. All patients received standard chemotherapy with sodium stibogluconate starting on Day 0. The vaccine was safe and well tolerated, and induced both humoral and cell-mediated immune responses. Furthermore, intracellular cytokine staining showed an increase in the proportion of memory LEISH-F1-specific IL-2(+) CD4 T-cells after vaccination, which was associated with clinical cure. This clinical trial shows that the LEISH-F1+MPL-SE vaccine is safe and immunogenic in patients with ML.


Subject(s)
Antigens, Protozoan/immunology , Antimony Sodium Gluconate/therapeutic use , Antiprotozoal Agents/therapeutic use , Leishmaniasis Vaccines/immunology , Leishmaniasis, Mucocutaneous/prevention & control , Adult , Antibodies, Protozoan/blood , Antibodies, Protozoan/immunology , Antibody Formation , Antimony Sodium Gluconate/administration & dosage , Antiprotozoal Agents/administration & dosage , Cytokines/immunology , Double-Blind Method , Endpoint Determination , Female , Humans , Immunoglobulin G/blood , Immunoglobulin G/immunology , Leishmaniasis Vaccines/administration & dosage , Leishmaniasis Vaccines/adverse effects , Leishmaniasis, Mucocutaneous/immunology , Male , Middle Aged , Th1 Cells/immunology , Young Adult
6.
Clin Vaccine Immunol ; 14(9): 1173-81, 2007 Sep.
Article in English | MEDLINE | ID: mdl-17626159

ABSTRACT

We evaluated whether four recombinant antigens previously used for vaccination against experimental infection with Leishmania (Leishmania) major could also induce protective immunity against a challenge with Leishmania (Viannia) braziliensis, the species responsible for 90% of the 28,712 annual cases of cutaneous and mucocutaneous leishmaniasis recorded in Brazil during the year of 2004. Initially, we isolated the homolog genes encoding four L. (V.) braziliensis antigens: (i) homologue of receptor for activated C kinase, (ii) thiol-specific antioxidant, (iii) Leishmania elongation and initiation factor, and (iv) L. (L.) major stress-inducible protein 1. At the deduced amino acid level, all four open reading frames had a high degree of identity with the previously described genes of L. (L.) major being expressed on promastigotes and amastigotes of L. (V.) braziliensis. These genes were inserted into the vector pcDNA3 or expressed as bacterial recombinant proteins. After immunization with recombinant plasmids or proteins, BALB/c mice generated specific antibody or cell-mediated immune responses (gamma interferon production). After an intradermal challenge with L. (V.) braziliensis infective promastigotes, no significant reduction on the lesions was detected. We conclude that the protective immunity afforded by these four vaccine candidates against experimental cutaneous leishmaniasis caused by L. (L.) major could not be reproduced against a challenge with L. (V.) braziliensis. Although negative, we consider our results important since they suggest that studies aimed at the development of an effective vaccine against L. (V.) braziliensis, the main causative agent of cutaneous leishmaniasis in the New World, should be redirected toward distinct antigens or different vaccination strategies.


Subject(s)
Antigens, Protozoan/immunology , Leishmania braziliensis/immunology , Leishmaniasis, Cutaneous/immunology , Leishmaniasis, Mucocutaneous/immunology , Protozoan Vaccines/immunology , Amino Acid Sequence , Animals , Antibodies, Protozoan/biosynthesis , Antibodies, Protozoan/immunology , Antigens, Protozoan/biosynthesis , Antigens, Protozoan/genetics , Disease Models, Animal , Heat-Shock Proteins/biosynthesis , Heat-Shock Proteins/genetics , Heat-Shock Proteins/immunology , Humans , Immunoassay/methods , Leishmania braziliensis/genetics , Leishmaniasis, Cutaneous/parasitology , Leishmaniasis, Cutaneous/prevention & control , Leishmaniasis, Mucocutaneous/parasitology , Leishmaniasis, Mucocutaneous/prevention & control , Life Cycle Stages , Male , Mice , Mice, Inbred BALB C , Molecular Sequence Data , Open Reading Frames , Peptide Initiation Factors/biosynthesis , Peptide Initiation Factors/genetics , Peptide Initiation Factors/immunology , Protozoan Proteins/biosynthesis , Protozoan Proteins/genetics , Protozoan Proteins/immunology , Protozoan Vaccines/genetics , Protozoan Vaccines/pharmacology , Vaccines, Synthetic/genetics , Vaccines, Synthetic/immunology , Vaccines, Synthetic/pharmacology
7.
Trop Med Int Health ; 10(9): 856-62, 2005 Sep.
Article in English | MEDLINE | ID: mdl-16135192

ABSTRACT

Mucocutaneous leishmaniasis (MCL) is an important health problem in many rural areas of Latin America, but there are few data on the results of programmatic approaches to control the disease. We report the results of a control programme in San Martin de Pangoa District, which reports one of the highest prevalences of MCL in Peru. For 2 years (2001--2002), the technicians at the health post were trained in patient case management, received medical support and were supplied with antimonials. An evaluation after 2 years showed the following main achievements: better diagnosis of patients, who were confirmed by microscopy in 34% (82/240) of the cases in 2001 and 60% of the cases (153/254) in 2002; improved follow-up during treatment: 237 of 263 (90%) patients who initiated an antimonial therapy ended the full treatment course; improved follow-up after treatment: 143 of 237 (60%) patients who ended their full treatment were correctly monitored during the required period of 6 (cutaneous cases) or 12 (mucosal cases) months after the end of treatment. These achievements were largely due to the human and logistical resources made available, the constant availability of medications and the close collaboration between the Ministry of Health, a national research institute and an international non-governmental organization. At the end of this period, the health authorities decided to register a generic brand of sodium stibogluconate, which is now in use. This should allow the treatment of a significant number of additional patients, while saving money to invest in other facets of the case management.


Subject(s)
Leishmaniasis, Mucocutaneous/prevention & control , Program Evaluation/methods , Antimony/therapeutic use , Antiprotozoal Agents/therapeutic use , Health Care Costs , Health Services Accessibility , Humans , Leishmaniasis, Mucocutaneous/epidemiology , Peru/epidemiology , Prevalence , Program Evaluation/economics , Rural Health , Treatment Outcome
10.
11.
Brasília; Fundaçäo Nacional de Saúde; 1998. 118 p. ilus, map, tab, graf.
Monography in Portuguese | Coleciona SUS | ID: biblio-919778
17.
Bull World Health Organ ; 75(1): 39-44, 1997.
Article in English | MEDLINE | ID: mdl-9141749

ABSTRACT

American mucocutaneous leishmaniasis is an important health problem in Peru, particularly in the mountainous Cuzco Region, where 25% of all new cases reported in 1989 were located. Cases have increased considerably since the beginning of the 1980s, when large-scale seasonal migration to endemic zones occurred, particularly the forest area of Madre de Dios, following the discovery of new gold deposits there, and the deterioration in the economic situation in Peru. Following the lack of official response from the Peruvian government, hundreds of people suffering from leishmaniasis in the Cuzco area formed self-help associations with the objective of obtaining the drugs needed to treat their disease. The major achievement of this spontaneous movement, which was supported by several public and private institutions, was to encourage sick people, particularly patients with mucosal lesions, to emerge from isolation. As a result, the prevalence and incidence of the disease have now considerably decreased in the region.


PIP: The deterioration in Peru's economic situation and the discovery of new gold deposits in the mountainous Cuzco Region have been associated with a considerable increase in cases of American mucocutaneous leishmaniasis. Following a lack of government response to this serious health problem, people with leishmaniasis in the town of Sicuani formed a patients' association in 1983 to try to obtain appropriate drugs for treatment. In 1983-93, eight additional patients' associations were established and, in 1990, these associations (representing 1648 members) united with health authorities and other institutions in the Cuzco Region to form a committee to coordinate their activities. The role of these associations was studied in field work conducted in the region in 1993. In interviews, association activists expressed demands that the government make free drugs available, offer financial compensation to those who acquire the disease through work, improve working conditions in the mines and living conditions for migrant workers, and identify other seasonal employment opportunities in order to prevent migration to the mining areas. The leishmaniasis movement, which originated as a spontaneous initiative, has become more structured and organized over time. A control strategy based on active case finding, early diagnosis, and early treatment of disease has been defined. A major achievement of the patients' associations, especially in Sicuani and Ocongate, has been to encourage sick people to emerge from their isolation. This program provides an example of successful multisectoral coordination and community participation of potential relevance in other countries where mucocutaneous leishmaniasis is endemic.


Subject(s)
Leishmaniasis, Mucocutaneous/prevention & control , Self-Help Groups , Animals , Antiprotozoal Agents/therapeutic use , Humans , Incidence , Leishmania braziliensis , Leishmaniasis, Mucocutaneous/epidemiology , Leishmaniasis, Mucocutaneous/parasitology , Peru/epidemiology , Prevalence , Self-Help Groups/organization & administration , Socioeconomic Factors , Transients and Migrants
19.
Brasília; Fundação Nacional de Saúde; 2 ed; 1997. 39 p. ilus, tab.
Monography in Portuguese | Coleciona SUS | ID: biblio-926313
SELECTION OF CITATIONS
SEARCH DETAIL
...